About Sarfez Pharmaceuticals
Sarfez Pharmaceuticals is a company based in Vienna (United States) founded in 2017 by Salim Shah. Sarfez Pharmaceuticals offers products and services including SOAANZ.
- Headquarter Vienna, United States
- Founders Salim Shah
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sarfez Cures India Private Limited
- Date of Incorporation 25 Jul, 2017
- Jurisdiction Dehradun, Uttarakhand, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2.26 M (USD), Grant
Sep 27, 2017
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sarfez Pharmaceuticals
Sarfez Pharmaceuticals offers a comprehensive portfolio of products and services, including SOAANZ.
Tablets for treating edema in heart failure and kidney disease.
Funding Insights of Sarfez Pharmaceuticals
Investors in Sarfez Pharmaceuticals
Sarfez Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Sarfez Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sarfez Pharmaceuticals
Investment portfolio details for Sarfez Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sarfez Pharmaceuticals
Detailed financials for Sarfez Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sarfez Pharmaceuticals Comparisons
Peer comparison for Sarfez Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sarfez Pharmaceuticals
Detailed competitors of Sarfez Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sarfez Pharmaceuticals
Complete news archive for Sarfez Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sarfez Pharmaceuticals
Sarfez Pharmaceuticals was founded in 2017.
Sarfez Pharmaceuticals is headquartered in Vienna, United States.
Fatima Khwaja is the current CEO of Sarfez Pharmaceuticals.
Sarfez Pharmaceuticals is focused on improving existing drugs using proprietary its extended-release formulation technology primarily to treat cardiovascular and kidney diseases. The company has developed formulation technologies such as matrix-based extended-release (MEXFOR), rapid-action orally-disintegrating technology (ROTEC) self-emulsifying drug delivery system (SEEDS). Its lead candidate is an extended release diuretic is being evaluated in clinical trials. Its RD pipeline has 8 programs which are either protein inhibitors or novel loop diuretics and are at different stages of development for hypertension, cardiac fibrosis, pancreatitis, diabetic nephropathy, nephrotic syndrome and congestive heart failure. The company has the alliances with Recipharm, Hetero Syngene.
Sarfez Pharmaceuticals offers SOAANZ.
Sarfez Pharmaceuticals has 1 investor. Key investors include HHS.